Experience

Indivior plc

in connection with the Relationship Agreement and settlement reached with the Company’s largest shareholder, the activist investor Scopia Management

Parkinson's UK

on its acquisition of assets relating to the research, development, manufacture and marketing of glial-cell line-derived neurotrophic factor (GDNF), a potentially disease-modifying treatment for Parkinson's disease

SK Holdings

on its acquisition of Yposkesi, a French market leader in gene therapy and viral vector manufacturing

Acacia Research Corporation

on its entry into an agreement with Link Fund Solutions Limited to purchase shares in up to 19 public and private life sciences companies from the LF Equity Income Fund for up to £223.9 million.

Achilles Vaccines

assisting leading Italian vaccine-developer Achilles Vaccines on various projects, including the creation of a platform for streamlining the research and development of new vaccines (including against COVID-19) and the start of a collaboration with vAMRes Lab at Toscana Life Sciences (TLS) Foundation (based in Siena, Italy) on a research project for the development of human monoclonal antibodies against COVID-19, with the aim of using them for prophylactic/therapeutic purposes and as molecular baits for the discovery of vaccine antigens. We also advised on Italian and German finance, IP and regulatory aspects of its EUR 46 million venture loan financing from EMF EU Malaria Fund (a fund linked to EIB)

FederFARMACO

a company representing pharmaceutical wholesalers, on regulatory affairs and intellectual property matters


Life science notes blog

Find analysis of the latest legal developments relevant to the life sciences

Subscribe now

Key contacts

Alan Montgomery photo

Alan Montgomery

Partner, Head of Pharmaceuticals Sector, Chair of India Group, London and India Group

Chris Parker KC photo

Chris Parker KC

Partner, Head of Pharmaceuticals Sector, London and Africa Group